“A vaccine that works really well is the best kind of medical intervention. But a vaccine that gives partial protection is a headache. Sanofi Pasteur has developed a tetravalent vaccine which is 60.8% protective against symptomatic dengue in children in Latin American countries where dengue is endemic.”
Read more: Richard Lehman’s journal review—12 January 2015. BMJ Blogs
“A tetravalent dengue vaccine has shown efficacy against dengue fever and severe dengue fever and led to fewer hospitalisations in a randomised, blinded, placebo controlled trial.”
Read more: Trial results raise hope for dengue fever vaccine.